Expression of Interest call 2018

International Rare Cancer Initiative Expression of Interest call 2018 for new rare cancer working groups 2018

The driving mission of IRCI is to facilitate the development and delivery of hypothesis driven interventional clinical trials for patient with rare cancer. The initiative to date has convened 9 groups and opened 7 trials. In recognition of the requirement to coordinate trial development internationally (to maximise funder approval and delivery success), IRCI is establishing a number of new international rare cancer groups. Future IRCI groups/studies will benefit from the broad international reach of the IRCI partner members, and application of key lessons learnt from the initial set of IRCI trials.

IRCI is running an EOI call for new working groups who wish to develop an international trial in a rare cancer. If the EOI is successful, IRCI will support the group chairs to make international connections to establish a group of interested parties, will coordinate meetings alongside ASCO or other international conferences, and will be able to provide information and advice on how to approach parallel funding applications and feasibility.

EOI submission

To submit an EOI to establish a new IRCI rare cancer disease group:

  1. Read the below Terms and Conditions for establishing a new rare cancer group
  2. Complete the EOI form
  3. Send EOI form to by 27th April 2018 (this has been extended from 5th April).

Your EOI will be shared with the IRCI Board of Directors and their countries respective clinical communities.

Next steps

At ASCO 2018 the IRCI Board will assess where there is shared interest to collaborate internationally and where there is scope to deliver a feasible hypothesis driven practice changing clinical trial. Feedback will be provided post ASCO 2018 to advise if your proposed IRCI rare cancer group has been selected to take forward.

Should you wish to discuss further, or if you have any questions, please contact

Terms and Conditions

Criteria for establishing new IRCI group

  • As a guide, cancers with a total incidence of between 2-6/100,000/year will be prioritised for inclusion (priority will not be given to rare molecular sub-types of a common cancer where it would be feasible to study the rare cancer as a stratification off a common cancer trial).
  • Where there is potential for a hypothesis driven interventional trial with a research treatments of interest for investigation, and sufficient patients for an international trial to be feasible (audits, registries or non-trial tissue collections are not within remit).
  • There is a lack of existing international forum to initiate discussion.
  • Enthusiastic commitment is essential from at least two investigators based in IRCI partner member countries who are willing to act as group leads. Broader group membership can be made up of colleagues from any country globally where there is interest to participate.
  • The Board might consider soliciting a project from the entire IRCI, which is not tied to individual groups or countries.

IRCI group lead/group expectation

  • It is expected that IRCI group meetings and telephone conferences should be supplemented by group activity offline. Group leads are responsible for building the broader group membership and self-managing the groups direction, driving progress to design/set up/deliver trial and to seek funding nationally (IRCI does not provide funding for trials).
  • As part of group discussions IRCI Group/trial leads are responsible for ensuring that a trial;
    • is feasible to deliver in the participating countries in a timely manner (in terms of patient numbers, treatment available, and trial design)- with consideration of statistical contingency plans if the trial is not approved in a planned country
    • is acceptable to patients and clinicians in participating countries
    • is in line with anticipated funders’ funding schemes/priorities
    • finds a home within national coordinating centres early to enable upfront operational management considerations

IRCI secretariat offer

  • The IRCI secretariat will facilitate a base level of meetings/teleconferences to support the group’s discussions – including a face to face meeting at ASCO each year plus 1 other face to face meeting at an appropriate international conference attended by your disease specialty colleagues.
  • No funding is available to support travel arrangements of IRCI group leads or IRCI group members to attend IRCI meetings. Meetings are planned alongside conferences at which it is expected your colleague would already be attending.
  • Support with funder level engagement/alignment, signposting and sharing of best practice.
  • IRCI groups will be facilitated for up to 3 years, at which time it would be anticipated that trial set up would be under way.